Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21NS.ClH |
| Molecular Weight | 331.903 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CC\C=C1/C2=C(CSC3=C1C=CC=C3)C=CC=C2
InChI
InChIKey=XUPZAARQDNSRJB-SJDTYFKWSA-N
InChI=1S/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H/b17-11+;
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H21NS |
| Molecular Weight | 295.442 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2670509Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8447840 | https://www.drugs.com/uk/dosulepin-capsules-25mg-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/9408183
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2670509
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8447840 | https://www.drugs.com/uk/dosulepin-capsules-25mg-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/9408183
cis-Dosulepin is a stereoisomer of Dothiepin (trade name Prothiaden, Dothep, Thaden, and Dopress; Dosulepin (INN, BAN) a tricyclic antidepressant that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. Dosulepin is used for the treatment of the major depressive disorder and neuropathic pain. Dosulepin is only Therapeutic Goods Administration and Medicines and Healthcare products Regulatory Agency approved for the treatment of the major depressive disorder. Dothiepin is not used in the United States. The central action of cis-dosulepin was compared with that of its antidepressant stereoisomer trans-dosulepin, cis-dosulepin exerted weaker anti-reserpine, anti-tetrabenazine, and 3H-5-HT (serotonin) uptake inhibiting actions than trans-dosulepin, but cis-dosulepin's inhibition of 3H-dopamine and 3H-norepinephrine uptake was slightly more potent than that of trans-dosulepin. On the other hand, cis-dosulepin exhibited extremely potent anticholinergic action in oxotremorine induced tremor, isolated ileum and the 3H-quinuclidinyl benzilate binding test. It also showed potent apomorphine enhancing the action and shortened the period of immobility in the forced swimming test in animals.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) |
8.4 null [pKi] | ||
| 18.0 nM [Kd] | |||
| 109.0 nM [Kd] | |||
| 38.0 nM [Kd] | |||
| 61.0 nM [Kd] | |||
| 92.0 nM [Kd] | |||
Target ID: CHEMBL228 Sources: https://www.drugbank.ca/drugs/DB09167 |
8.6 nM [Kd] | ||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9537821 |
46.0 nM [Kd] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
|||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Prothiaden Approved UseUnknown |
|||
| Primary | Prothiaden Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.6 ng/mL |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.7 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
29.49 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
51.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
84.95 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
117.6 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
458.7 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
576.42 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
961.69 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1586.14 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.4 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
22 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.58 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3735103/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOTHIEPIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.6% |
DOTHIEPIN plasma | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). | 2003-02 |
|
| Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. | 1999-08 |
|
| Antidepressant drugs and heart electrical field. | 1998 |
|
| Pharmacological profile of antidepressants and related compounds at human monoamine transporters. | 1997-12-11 |
|
| Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. | 1996 |
|
| Exacerbation of extrapyramidal symptoms with paroxetine. | 1995-09 |
|
| Extreme suicidality following serotonin syndrome. | 1995-09 |
|
| Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. | 1993-06-09 |
|
| [A case of choreoathetoid movements induced by anticholinergic drugs, trihexyphenidyl HCl and dosulepin HCl]. | 1992-09 |
|
| Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. | 1989-07 |
|
| [Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case]. | 1986-12 |
|
| A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder. | 1984-11 |
|
| A comparative study of the therapeutic effect and cardiotoxicity of dothiepin HCl and doxepin HCl in reactive depression. | 1981 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9408183
male Slc:Wistar rats: 40 mg/kg, PO
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:58 GMT 2025
by
admin
on
Mon Mar 31 17:48:58 GMT 2025
|
| Record UNII |
3H0042311V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID7047778
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
142133
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB01821MIG
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
CHEMBL1492500
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
3H0042311V
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
C78018
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
212-978-8
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
DBSALT001822
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
100000091934
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
6433931
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
m4748
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
31519
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
172130
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY | |||
|
897-15-4
Created by
admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |